Pre-clinical and clinical quality
Pre‑clinical and clinical quality is not about imposing pharmaceutical‑grade structures too early. It is about putting the right level of control in place at the right time, and ensuring that scientific work translates into data that regulators, inspectors, and partners can rely on.
Here we focus on how we support sponsors, investigators, service providers, and clinical units throughout the development lifecycle.
When quality starts to limit development instead of supporting it
Common trigger situations include:
Transitioning into regulated development
organisations move from exploratory research into GLP or GCP environments without having adjusted governance, documentation, and oversight accordingly.
Increasing trial complexity
multiple sites, CROs, laboratories, or vendors are introduced without a proportional increase in sponsor oversight capability.
Data credibility concerns
questions arise about traceability, consistency, or reliability of non‑clinical or clinical data.
Regulatory or partner exposure
audits, inspections, due diligence, or scientific advice highlight that quality arrangements may not withstand external scrutiny,
What fit-for-purpose quality looks like in development
Early integration of quality thinking
Quality should inform study design, not follow it. Embedding quality early reduces the need for extensive remediation later and supports smoother transitions into clinical phases.
Clear accountability across parties
Whether work is internal or outsourced, roles and responsibilities must be explicit. Sponsors ultimately remain accountable, and quality arrangements need to reflect this reality.
Focus on what is critical to quality
Modern regulatory expectations emphasise identification and control of critical‑to‑quality factors. Not everything needs the same level of control; what matters is that the right things are controlled well.
How QAlliance typically supports
Pre-clinical and clinical project management
- Integration of quality activities into project plans
- Clarification of responsibilities across sponsors, CROs, and service providers
- Coordination of documentation, timelines, and deliverables
GCP QA management
- Development or optimisation of GCP quality systems
- Oversight models adapted to trial complexity
- Support for clinical trial documentation, processes, and governance
Sponsor oversight
- Defining proportionate oversight strategies
- Assessing CRO and vendor performance
- Establishing structured communication and escalation paths
- Linking oversight activities to risk assessments and quality planning
Examples of development-phase challenges we help resolve
“We started trials before quality was fully in place.”
We help stabilise systems retrospectively without halting ongoing activities.
“Oversight exists, but feels fragmented.”
We align sponsor oversight, audits, and governance into a coherent control model.
“We are unsure which risks really matter to regulators.”
We identify critical‑to‑quality factors and refocus quality efforts accordingly.
“Early data might be questioned later.”
We strengthen traceability and documentation so data remains usable through later phases.
What to expect from us
Expect:
- Proportionate quality controls aligned with development stage
- Pragmatic support that respects scientific and operational realities
- Quality oversight that strengthens confidence without slowing progress
Don’t expect:
- Pharmaceutical over‑engineering at early stages
- Generic trial oversight models
- Academic interpretations of GxP without practical application
Weaknesses identified later in development or during regulatory review often trace back to early‑phase quality decisions. For this reason, development quality is most effective when aligned with the broader quality framework from the outset.
Pre‑clinical and clinical quality is tightly connected to:
- governance and leadership (accountability and escalation)
- quality systems (structure and risk management)
- operational quality (execution and consistency)
- audits and inspections (external evaluation)